Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Although prescribing information (PI) is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical ca...
Main Authors: | Paul T. Kocis, Kent E. Vrana |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-07-01
|
Series: | Medical Cannabis and Cannabinoids |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/507998 |
Similar Items
-
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
by: Joshua D. Brown
Published: (2020-03-01) -
Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity
by: Swapnali Chetia, et al.
Published: (2020-08-01) -
Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
by: Joseph J. Wakshlag, et al.
Published: (2020-09-01) -
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
by: Timo Woelfl, et al.
Published: (2020-11-01) -
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
by: Albert Batalla, et al.
Published: (2021-01-01)